Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Empire Genomics Licenses First Known DNA Biomarker for Multiple Myeloma

Published: Thursday, November 29, 2012
Last Updated: Thursday, November 29, 2012
Bookmark and Share
Detection of gene abnormalities may help patients and physicians determine the best approach to treatment, improve survival rate and lower treatment costs.

Empire Genomics announced it has acquired an exclusive license for patent pending novel genomic biomarkers from Emory University for use in developing a molecular diagnostic test that could help satisfy a large unmet medical need in determining ideal therapeutic treatment for multiple myeloma patients.

Recent data point to certain genetic biomarkers that may identify which patients would benefit from receiving treatment with the various therapies opposed to those that receive no benefit. The team is embarking in a phase II biomarker driven clinical trial using this technology to validate its power to predict outcomes in new generations of MM drugs.

"Developing a clinically validated multiple myeloma cancer theranostic assay with informative data would represent a major breakthrough in improving disease management," said Leon Bernal-Mizrachi, M.D., Assistant Professor of Hematology and Medical Oncology, Emory University School of Medicine "It would fulfill an unmet medical need to help patients with multiple myeloma better plan treatment options that will help produce the best outcomes."

Multiple myeloma accounts for approximately 10% of blood based cancers, with an estimated 21,700 new cases and 10,710 deaths in the US in 2012. Multiple myeloma is a malignant blood cell cancer that is increasing in frequency in today's aging population. While advances in therapeutic treatments have improved the response rate, there are significant side effects to these very costly treatments.

Empire Genomics is commercializing a genetic test for multiple myeloma that will guide treatments and reduce health care costs, while sparing patients the negative consequences of treatments that may not be effective. This new diagnostic test will be the first DNA biomarker test to direct treatment of multiple myeloma. Empire will explore the use of this biomarker in lymphoma patients as well.

"This is a meaningful breakthrough in the area of personalized medicine and we are excited to work with Emory University and Dr. Bernal-Mizrachi to bring it to the market to help oncologists make more informed treatment decisions for this dreadful disease," said Anthony Johnson, CEO of Empire Genomics.

Empire Genomics, a leader in field of personalized medicine, will use this test and others in development to continue to support and accelerate clinical trials and the creation of cancer companion diagnostics for therapies. It is expected that this test will be employed in clinical trials in the future as well as launched through clinical labs in early 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Grant to Fund Million Peaks Project
The European Research Council (ERC) has awarded a prestigious Advanced Grant to Prof. Peter Schoenmakers, Prof. Albert Polman and Prof. Huib Bakker, all three of whom work at the University of Amsterdam (UvA).
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!